Try a new search

Format these results:

Searched for:

person:frieda02

Total Results:

207


Cutis verticis gyrata

Yagerman, Sarah; Callahan, Shields; Terushkin, Vitaly; Meehan, Shane A; Pomeranz, Miriam Keltz; Friedman-Kien, Alvin
Cutis verticis gyrata that involves only the face isa rare presentation of this even rarer cutaneousanomaly. We present a 61-year-old man, whodeveloped primary essential progressive cutis verticisgyrata of the face.
PMID: 28329551
ISSN: 1087-2108
CID: 2494772

An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment

Curtiss, Paul; Strazzulla, Lauren C; Friedman-Kien, Alvin E
Kaposi's sarcoma is an angioproliferative neoplasm which has undergone considerable epidemiologic change since the original description by Moritz Kaposi in the late 1800s. This opportunistic neoplasm gained widespread notoriety within the US during the height of the AIDS epidemic, where it was frequently found co-occurring with opportunistic infections. With the advent of modern antiretroviral therapies, as well as an increasing number of individuals on immunosuppression for autoimmune disease or organ transplantation, the landscape of the immunocompromised individual has changed. It is now important for clinicians to be mindful of Kaposi's sarcoma manifesting in a growing variety of clinical contexts.
PMCID:5120640
PMID: 27804093
ISSN: 2193-8210
CID: 2297242

Cutis verticis gyrate

Yagerman, S; Callahan, S; Terushkin, V; Meehan, S A; Pomeranz, M K; Friedman-Kien, A
Cutis verticis gyrata that involves only the face is a rare presentation of this even rarer cutaneous anomaly. We present a 61-year-old man, who developed primary essential progressive cutis verticis gyrata of the face.
EMBASE:613847072
ISSN: 1087-2108
CID: 2396992

Postoperative pathergic pyoderma gangrenosum after aortic aneurysm repair [Letter]

Leventhal, Jonathan S; Tlougan, Brook E; Mandell, Jenny A; Friedman-Kien, Alvin E; Meehan, Shane A
PMID: 24164156
ISSN: 0011-9059
CID: 598562

Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes

Curreli, Francesca; Friedman-Kien, Alvin E; Flore, Ornella
Kaposi sarcoma-associated herpesvirus (KSHV) is linked with all clinical forms of Kaposi sarcoma and several lymphoproliferative disorders. Like other herpesviruses, KSHV becomes latent in the infected cells, expressing only a few genes that are essential for the establishment and maintenance of its latency and for the survival of the infected cells. Inhibiting the expression of these latent genes should lead to eradication of herpesvirus infection. All currently available drugs are ineffective against latent infection. Here we show, for the first time to our knowledge, that latent infection with KSHV in B lymphocytes can be terminated by glycyrrhizic acid (GA), a triterpenoid compound earlier shown to inhibit the lytic replication of other herpesviruses. We demonstrate that GA disrupts latent KSHV infection by downregulating the expression of latency-associated nuclear antigen (LANA) and upregulating the expression of viral cyclin and selectively induces cell death of KSHV-infected cells. We show that reduced levels of LANA lead to p53 reactivation, an increase in ROS, and mitochondrial dysfunction, which result in G1 cell cycle arrest, DNA fragmentation, and oxidative stress-mediated apoptosis. Latent genes are involved in KSHV-induced oncogenesis, and strategies to interfere with their expression might prove useful for eradicating latent KSHV infection and have future therapeutic implications
PMCID:1051998
PMID: 15765147
ISSN: 0021-9738
CID: 49656

Detection and quantitation of Kaposi's sarcoma-associated herpesvirus (KSHV) by a single competitive-quantitative polymerase chain reaction

Curreli, Francesca; Robles, Monica A; Friedman-Kien, Alvin E; Flore, Ornella
Kaposi's sarcoma-associated herpesvirus is a novel herpesvirus linked to AIDS-related neoplasms. Currently it is difficult to evaluate the number of virions in viral preparation or in samples obtained from patients with Kaposi's sarcoma (KS), since no protocol for determining the plaque forming units of KSHV exists. We constructed a fragment of a different size than the target viral DNA to carry out a competitive-quantitative PCR. Both fragment and viral DNA were added to a single PCR reaction to compete for the same set of primers. By knowing the amount of the competitor added to the reaction, we could determine the number of viral DNA molecules. We used this assay successfully to detect and quantify KSHV genomes from KS skin biopsies and pleural effusion lymphoma, and from different viral preparations. To date, this is the most convenient and economic method that allows an accurate and fast viral detection/quantitation with a single PCR
PMID: 12505642
ISSN: 0166-0934
CID: 33606

Kaposi's Sarcoma-associated Herpesvirus (KSHV/HHV8) Quantification and acute infection of human endothelial cell cultures

Diana S; Curreli F; Cerimele F; Friedman-Kien AE; Flore O
Kaposi's Sarcoma-associated herpesvirus (KSHV) is a novel herpesvirus linked to Kaposi's sarcoma and some lymphoproliferative diseases. Recently we demonstrated KSHV serial transmission and transformation of primary human endothelial cells and keratinocytes. In this study we characterize transcription and expression of KSHV genes during acute infection. Concentrated virions from TPA-induced BC-3 cell supernatant were quantitated by competitive PCR and used to infect in vitro primary and SV40-immortalized bone marrow endothelial cells and umbilical vein endothelial cells. Spindle cell morphology and lytic plaques were identified after infection, and viral DNA was detected by PCR after two passages. Six days post-infection, RT-PCRs and immunofluorescence revealed transcription of KSHV latent and lytic genes. No changes were evident in the production of human IL6, IL8, MIP-1a, MIP-1beta, RANTES, sTNFr 1/2 after infection. These studies confirm that KSHV can establish a productive infection in human endothelial cells in culture, and provide a rapid method for viral titration
EMBASE:2007040805
ISSN: 0019-1655
CID: 70096

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma

Tulpule, Anil; Groopman, Jerome; Saville, M Wayne; Harrington, William Jr; Friedman-Kien, Alvin; Espina, Byron M; Garces, Carlos; Mantelle, Lily; Mettinger, Karl; Scadden, David T; Gill, Parkash S
BACKGROUND: Treatment options are limited for patients with advanced acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (AIDS-KS) whose disease has progressed after receiving therapy with liposomal anthracyclines or combination chemotherapy with doxorubicin (Adriamycin), bleomycin, and vincristine (ABV). This study was performed to assess the safety and efficacy of a novel dose and schedule of paclitaxel in patients with AIDS-KS who failed to respond to previous systemic chemotherapy. METHODS: This was an open-label, multicenter Phase II study. Eligible patients had advanced AIDS-KS consisting of at least 25 mucocutaneous lesions, visceral disease, or lymphedema, and had failed to respond to at least one previous systemic chemotherapy regimen. Patients were treated with paclitaxel at a dose of 100 mg/m(2) given intravenously over 3 hours, every 2 weeks. Primary efficacy end points were tumor response, time to progression, time to treatment failure, and survival. Quality of life and adverse events were evaluated using the Symptom Distress Scale (SDS) and the World Health Organization Toxicity Criteria, respectively. RESULTS: One hundred and seven male patients with advanced AIDS-KS were enrolled from nine participating sites. The median entry CD4+ lymphocyte count was 41/mm(3) (range 0-1139). Previous treatment regimens included ABV in 52, liposomal daunorubicin in 49, and liposomal doxorubicin in 40 patients. Forty-one patients (38%) received two or more previous chemotherapy regimens. Protease inhibitor use during the study was reported by 82 (77%) patients overall; 47 patients (44%) were receiving a protease inhibitor before study entry. Complete or partial response was documented in 60 patients (56%). The median duration of response was 8.9 months. Major response rate was similar when comparing patients not on a protease inhibitor at the time of response (59%) with patients on a protease inhibitor at time of response (54%). However, protease inhibitor use had a significant impact on survival (P = 0.04). Grade 4 neutropenia was reported in 35% of patients; other life-threatening side effects were uncommon. Significant improvements were seen in the total quality of life scores measured by the SDS, including significant improvement in KS-related symptoms such as facial disease, tumor-associated edema, and pulmonary involvement. CONCLUSION: Paclitaxel given every 2 weeks induces major tumor regression in the majority of patients with advanced KS who failed to respond to previous systemic chemotherapy. Paclitaxel is associated with significant improvement in quality of life with acceptable toxicity and should be considered as an effective treatment option for patients with advanced KS
PMID: 12115328
ISSN: 0008-543x
CID: 49657

Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication

Curreli, Francesca; Cerimele, Francesca; Muralidhar, Sumitra; Rosenthal, Leonard J; Cesarman, Ethel; Friedman-Kien, Alvin E; Flore, Ornella
Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a cellular dihydrofolate reductase (DHFR) homologue. Methotrexate (MTX), a potent anti-inflammatory agent, inhibits cellular DHFR activity. We investigated the effect of noncytotoxic doses of MTX on latency and lytic KSHV replication in two KSHV-infected primary effusion lymphoma cell lines (BC-3 and BC-1) and in MTX-resistant BC-3 cells (MTX-R-BC-3 cells). Treatment with MTX completely prevented tetradecanoyl phorbol acetate-induced viral DNA replication and strongly decreased viral lytic transcript levels, even in MTX-resistant cells. However, the same treatment had no effect on transcription of cellular genes and KSHV latent genes. One of the lytic transcripts inhibited by MTX, ORF50/Rta (open reading frame), is an immediate-early gene encoding a replication-transcription activator required for expression of other viral lytic genes. Therefore, transcription of genes downstream of ORF50/Rta was inhibited, including those encoding the viral G-protein-coupled receptor (GPCR), viral interleukin-6, and K12/kaposin, which have been shown to be transforming in vitro and oncogenic in mice. Resistance to MTX has been documented in cultured cells and also in patients treated with this drug. However, MTX showed an inhibitory activity even in MTX-R-BC-3 cells. Two currently available antiherpesvirus drugs, cidofovir and foscarnet, had no effect on the transcription of these viral oncogenes and ORF50/Rta. MTX is the first example of a compound shown to downregulate the expression of ORF50/Rta and therefore prevent viral transforming gene transcription. Given that the expression of these genes may be important for tumor development, MTX could play a role in the future management of KSHV-associated malignancies
PMCID:136151
PMID: 11967335
ISSN: 0022-538x
CID: 39672

Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma

Miles, Steven A; Dezube, Bruce J; Lee, Jeannette Y; Krown, Susan E; Fletcher, Mary Ann; Saville, M Wayne; Kaplan, Lawrence; Groopman, Jerome; Scadden, David T; Cooley, Timothy; Von Roenn, Jamie; Friedman-Kien, Alvin
OBJECTIVE: To assess the efficacy, safety and tolerance of oral 9-cis-retinoic acid in HIV-infected patients with Kaposi's sarcoma. METHODS: Sixty-six patients with AIDS-related Kaposi's sarcoma were enrolled at 14 centers; 60 received the study medication and were analyzed and, of these, 45 (75%) had received prior therapy for Kaposi's sarcoma. Once daily oral 9-cis-retinoic acid (alitretinoin, Panretin) was administered at doses up to 140 mg/m2. Most patients (72%) received a maximum dose of 100 mg/m2. Response was assessed using AIDS Clinical Trials Group (ACTG) criteria. RESULTS: The median age was 38 years and the median absolute CD4 cell count was 194 x 10(6) cells/l (range 6-784 x 10(6)). Despite the use of three- and four-drug antiviral regimens (83%), the median HIV RNA at baseline was 8701 copies/ml [range < 500 (lower limit of detection) to 4.24 x 10(6)]. The tumor response rate was 37% (95% confidence interval 25-49). Tumor response was associated with improved quality-of-life measures. There was a significant increase in interleukin 6 (IL-6) levels from baseline to week 4. Responders had significantly lower baseline soluble IL-6 receptor levels (P = 0.029) than non-responders. The median time to response was 9 weeks (mean, 13 weeks; range, 4-36). HIV RNA levels did not change significantly during therapy nor did they correlate with tumor responses. Study drug was discontinued by 28 patients for adverse events, which included headache (13) and skin toxicity (10). CONCLUSION: Oral 9-cis-retinoic acid is an active antitumor drug for AIDS-related Kaposi's sarcoma. Treatment is associated with skin and constitutional toxicity and further studies are needed to improve its long-term tolerance
PMID: 11834954
ISSN: 0269-9370
CID: 49658